keyword
MENU ▼
Read by QxMD icon Read
search

Denosumab

keyword
https://www.readbyqxmd.com/read/28105885/denosumab-in-patients-with-giant-cell-tumor-of-bone-in-norway-results-from-a-nationwide-cohort
#1
Kjetil Boye, Nina Louise Jebsen, Olga Zaikova, Heidi Knobel, Ayca M Løndalen, Clement S Trovik, Odd R Monge, Kirsten Sundby Hall
BACKGROUND: Denosumab is a relatively new treatment option for patients with giant-cell tumor of bone (GCTB). The purpose of this study was to report the results for patients treated in Norway. MATERIALS AND METHODS: Patients treated with denosumab for GCTB were identified from the clinical databases at the Norwegian sarcoma reference centers. Data were retrieved from the clinical databases and supplemented by retrospective review of patient records. Denosumab was given as a subcutaneous injection every 4 weeks with loading doses on day 8 and 15 in cycle 1...
January 20, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28101196/denosumab-treatment-of-inoperable-or-locally-advanced-giant-cell-tumor-of-bone
#2
Aneta Borkowska, Tomasz Goryń, Andrzej Pieńkowski, Michał Wągrodzki, Ewelina Jagiełło-Wieczorek, Paweł Rogala, Milena Szacht, Piotr Rutkowski
Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive tumor that rarely metastasizes and typically occurs in the bones. At present, the primary treatment for GCTB is curettage with local adjuvants. Giant cells express receptor activator of nuclear factor-κB ligand (RANKL). Denosumab, a RANKL inhibitor appears to present an effective therapeutic option in advanced cases of GCTB. The aim of the present study was to confirm the efficacy of denosumab in large group of patients with locally advanced GCTB...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28098118/safety-of-denosumab-in-dialysis-patients-on-calcium-and-vitamin-d-supplements
#3
Asad Ullah, K Abdulnabi, A Khalil, J Alexander, P Pai, V Mishra
No abstract text is available yet for this article.
January 2017: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/28098117/denosumab-for-the-treatment-of-bisphosphonate-resistant-hypercalcemia-in-a-hemodialysis-patient
#4
Omar Dahmani, Christine Sophoclis, Malika Kebir, Djemai Bouguern, Aboubacry Sakho, Pascale Demarchi
The acronym of malignancy, iatrogenic, intoxication and immobilization, sarcoidosis, hyperparathyroidism and hyperthyroidism, milk-alkali syndrome, and paget is very helpful in diagnosing hypercalcemia. We report on a 94-year-old patient with history of end-stage renal failure secondary to benign nephroangiosclerosis, who was on maintenance hemodialysis during dialysis, his blood chemistry revealed mild hypercalcemia (2.66 mmol/L) with normal level of intact primary hyperparathyroidism (32.37 ng/mL) mandating the discontinuation of Vitamin D[3]...
January 2017: Saudi Journal of Kidney Diseases and Transplantation
https://www.readbyqxmd.com/read/28096932/contemporary-agents-in-the-management-of-metastatic-castration-resistant-prostate-cancer
#5
REVIEW
Anil Kapoor, Christopher Wu, Bobby Shayegan, Adrian P Rybak
Docetaxel-based chemotherapy has been the standard of care for metastatic castration-resistant prostate cancer (mCRPC) since 2004. Over the past few years, there has been a significant paradigm shift in the treatment landscape of this disease. A deeper understanding of prostate cancer biology, along with the development of novel agents has created hope towards treating chemotherapy-naïve and resistant disease. Following the implementation of docetaxel as the first-line therapy for mCRPC, five novel therapies have demonstrated survival benefit in mCRPC...
November 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28092987/emerging-treatment-approaches-for-myeloma-related-bone-disease
#6
Maria Gavriatopoulou, Meletios A Dimopoulos, Efstathios Kastritis, Evangelos Terpos
Multiple myeloma is characterized by the presence of osteolytic lesions that leads to devastating skeletal-related events in the majority of patients. Myeloma bone disease is attributed to increased osteoclastic and suppressed osteoblastic activity. Areas covered: Bisphosphonates remain the main treatment option, however they have limitations on their own. Understanding the pathogenesis of myeloma bone disease may provide a roadmap for new therapeutic approaches. The pathway of RANKRANKLOPG pathway has revealed denosumab, a monoclonal antibody targeting RANKL as a novel emerging therapy for myeloma-related bone disease...
January 17, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28087216/denosumab-and-alendronate-treatment-in-patients-with-back-pain-due-to-fresh-osteoporotic-vertebral-fractures
#7
Tomoko Tetsunaga, Tomonori Tetsunaga, Keiichiro Nishida, Masato Tanaka, Yoshihisa Sugimoto, Tomoyuki Takigawa, Yoshitaka Takei, Toshifumi Ozaki
INTRODUCTION: Denosumab specifically inhibits the receptor activator for nuclear factor-kappa B ligand (RANKL), and prevents osteoporotic fractures. Several reports have analyzed the effects of denosumab and alendronate alone on bone mineral density (BMD) or reduction of fracture risk. The objective of this study was to analyze the effects of antiresorptive osteoporosis pharmacotherapy on pain relief in patients with fresh vertebral fracture. METHODS: This retrospective, single-center study included 80 patients (10 males, 70 females) with fresh osteoporotic vertebral fractures treated using denosumab at a dose of 60 mg subcutaneously every 6 months (40 patients) or alendronate at a dose of 35 mg orally every week (40 patients) for 6 months in our hospital...
January 10, 2017: Journal of Orthopaedic Science: Official Journal of the Japanese Orthopaedic Association
https://www.readbyqxmd.com/read/28078478/hypercalcaemia-and-hypocalcaemia-finding-the-balance
#8
REVIEW
Jean-Jacques Body, Daniela Niepel, Giuseppe Tonini
CALCIUM METABOLISM IN CANCER AND HYPERCALCAEMIA OF MALIGNANCY: The balance between bone formation and resorption may be disrupted in patients with cancer, leading either to increased bone resorption, calcium release, and possibly hypercalcaemia, or to increased bone formation, sequestration of calcium, and possibly hypocalcaemia. In adults, hypercalcaemia of malignancy is most common in patients with tumours that produce factors that induce osteoclast activation and enhance bone resorption...
January 12, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28078198/multidisciplinary-approach-to-management-of-temporal-bone-giant-cell-tumor
#9
Taija K Nicoli, Riste Saat, Risto Kontio, Anna Piippo, Maija Tarkkanen, Jussi Tarkkanen, Jussi Jero
Background Giant cell tumors (GCTs) are rare osseous tumors that rarely appear in the skull. Methods We review the clinical course of a 28-year-old previously healthy woman with a complicated GCT. Results The reviewed patient presented with a middle cranial fossa tumor acutely complicated by reactive mastoiditis. Left tympanomastoidectomy was performed for drainage of the mastoiditis and for biopsies of the tumor. Due to the challenging tumor location, the patient was treated with denosumab, a fully humanized monoclonal antibody against receptor activator of nuclear factor kappa-B ligand, for 7 months, which resulted in significant preoperative tumor shrinkage...
July 2016: Journal of Neurological Surgery Reports
https://www.readbyqxmd.com/read/28078129/osteonecrosis-of-the-jaw-associated-with-ziv-aflibercept
#10
Hani Mawardi, Peter Enzinger, Nadine McCleary, Reshma Manon, Alessandro Villa, Nathaniel Treister, Sook-Bin Woo
Medication-related osteonecrosis of the jaw (MRONJ) has been associated with medications that include bisphosphonates (BPs), denosumab, bevacizumab and sunitinib. Ziv-aflibercept is a recombinant human vascular endothelial growth factor (VEGF) receptor which has been used to treat patients with various advanced solid tumors. We report three patients without a history of the use of medications known to cause MRONJ presenting with jaw osteonecrosis typical for MRONJ following therapy with ziv-aflibercept. All patients had metastatic gastrointestinal cancer treated with ziv-aflibercept and were evaluated for MRONJ because of exposed bone in the oral cavity...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28077015/atypical-femoral-fractures-mimicking-metastatic-lesions-in-2-patients-taking-denosumab
#11
Daniel C Austin, Michael T Torchia, Christian M Klare, Robert V Cantu
No abstract text is available yet for this article.
January 12, 2017: Acta Orthopaedica
https://www.readbyqxmd.com/read/28067568/improving-community-prescribing-of-post-fracture-denosumab-after-discharge
#12
Helen Wood, Harriet Lewis, Rachael Ward, Tarun Solanki, Prabhath Fernando
BACKGROUND: In the UK, denosumab is usually started by hospital clinicians and continued by primary care physicians in the community, but in the authors' region denosumab is a 'green light' drug, only prescribed by the primary care team. The authors suspected that a proportion of patients who were recommended to start the drug after a neck of femur fracture were not receiving this on discharge. They aimed to improve the prescribing of denosumab by implementing a quality improvement project...
January 2, 2017: British Journal of Hospital Medicine
https://www.readbyqxmd.com/read/28058444/frequency-of-discontinuation-of-injectable-osteoporosis-therapies-in-us-patients-over-2%C3%A2-years
#13
A Modi, S Sajjan, R Insinga, J Weaver, E M Lewiecki, S T Harris
: Little is known about treatment patterns with injectable osteoporosis therapies. At 12 months, the probability of discontinuation was 69.1% among patients using ibandronate, followed by teriparatide (67.1%), zoledronic acid (59.2%), and denosumab (48.8%). By 24 months, discontinuation was higher for each treatment. The majority of US patients discontinue injectable osteoporosis treatment by the end of the first year following initiation. INTRODUCTION: This study was designed to assess the frequency of treatment discontinuation over time among patients who initiate injectable osteoporosis therapies...
January 5, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28057913/humoral-hypercalcemia-in-uterine-cancers-a-case-report-and-literature-review
#14
Vijeyaluxmy Motilal Nehru, Gwenalyn Garcia, Juan Ding, Fanyi Kong, Qun Dai
BACKGROUND Paraneoplastic hypercalcemia is a well-described complication associated with a variety of malignancies. However, its incidence in gynecological malignancies is low. CASE REPORT A 53-year-old woman presented with progressive abdominal distention and irregular vaginal bleeding of several weeks' duration. A contrast CT abdomen and pelvis was significant for a mass in the lower uterine/cervical region, multiple peritoneal and omental masses, enlarged pelvic and paraaortic lymph nodes, and large-volume ascites...
January 6, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28035494/antiresorptive-agent-related-osteonecrosis-of-the-jaw-position-paper-2017-of-the-japanese-allied-committee-on-osteonecrosis-of-the-jaw
#15
Toshiyuki Yoneda, Hiroshi Hagino, Toshitsugu Sugimoto, Hiroaki Ohta, Shunji Takahashi, Satoshi Soen, Akira Taguchi, Toshihiko Nagata, Masahiro Urade, Takahiko Shibahara, Satoru Toyosawa
Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is an intractable, though rare, complication in cancer patients with bone metastases and patients with osteoporosis who are treated with antiresorptive agents, including bisphosphonates and denosumab. Despite the more than 10 years that have passed since the first cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ) were reported, our understanding of the epidemiology and pathophysiology of ARONJ remains limited, and data supported by evidence-based medicine are still sparse...
December 29, 2016: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/28027521/correlation-between-severe-infection-and-breast-cancer-metastases-in-the-eortc-10994-big-1-00-trial-investigating-innate-immunity-as-a-tumour-suppressor-in%C3%A2-breast-cancer
#16
Nathan Touati, Konstantinos Tryfonidis, Franco Caramia, Hervé Bonnefoi, David Cameron, Leen Slaets, Belinda S Parker, Sherene Loi
BACKGROUND: Breast cancer cells which express an innate immune signature regulated by interferon regulatory factor 7 (IRF7) have reduced metastatic potential. Infections can induce interferon signalling and may activate an anti-tumour immune response. We investigated whether 'severe infection' can be a clinical surrogate of this phenomenon and/or the presence of high levels of the IRF7 signature at diagnosis before neo-adjuvant chemotherapy (NACT) is associated with a reduced distant relapse risk, specifically in bones...
December 24, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/28011856/denosumab-is-a-long-term-option-for-the-management-of-parathyroid-carcinoma-related-refractory-hypercalcemia
#17
A Fountas, S Tigas, A Tsatsoulis
No abstract text is available yet for this article.
December 22, 2016: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/28011854/denosumab-as-a-long-term-palliative-therapy-in-parathyroid-carcinoma
#18
C V Tong, L T Loh, Z Hussein
No abstract text is available yet for this article.
December 22, 2016: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/28009753/efficacy-and-safety-of-selective-arterial-embolization-in-the-treatment-of-aneurysmal-bone-cyst-of-the-mobile-spine-a-retrospective-observational-study
#19
Silvia Terzi, Alessandro Gasbarrini, Mario Fuiano, Giovanni Barbanti Brodano, Riccardo Ghermandi, Stefano Bandiera, Stefano Boriani
STUDY DESIGN: Retrospective observational study. OBJECTIVE: Our aim is to define the efficacy and safety of serial selective arterial embolization (SAE) in the treatment of aneurysmal bone cysts, to explore potential treatment alternatives and to define a therapeutic algorithm. SUMMARY OF BACKGROUND DATA: Aneurysmal bone cyst (ABC) is a benign lesion with unpredictable behavior. Its treatment is challenging especially in poorly accessible surgical areas, such as spine and pelvis...
December 22, 2016: Spine
https://www.readbyqxmd.com/read/28008379/a-phase-2-trial-exploring-the-clinical-and-correlative-effects-of-combining-doxycycline-with-bone-targeted-therapy-in-patients-with-metastatic-breast-cancer
#20
C L Addison, D Simos, Z Wang, G Pond, S Smith, S Robertson, S Mazzarello, G Singh, L Vandermeer, R Fernandes, A Iyengar, S Verma, M Clemons
BACKGROUND: Bone-targeting agents (BTAs), such as bisphosphonates and denosumab, have demonstrated no discernable effects on tumour response or disease free/overall survival in patients with bone metastases from breast cancer. Doxycycline is both osteotropic and has anti-cancer effects. When combined with zoledronate in animal models, doxycycline showed significantly increased inhibition of tumour burden and increased bone formation. We evaluated the effects of adding doxycycline to ongoing anti-cancer therapy in patients with metastatic breast cancer...
November 2016: Journal of Bone Oncology
keyword
keyword
8329
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"